This article about
symptoms when in remission is
open access and worth the read.
https://www.ncbi.nlm.nih.gov/pmc/articles/pmc4734957/https://www.ncbi.nlm.nih.gov/pmc/articles/pmc4734957/ said...
IBD-IBS prevalence data are very variable due to heterogeneity in remission definition, diagnostic criteria and exclusion criteria. Pooling prevalences of the most homogeneous studies shows that about a third of quiescent IBD patients will suffer from IBS-like symptoms.
https://www.ncbi.nlm.nih.gov/pmc/articles/pmc4734957/ said...
Several pathogenic mechanisms can explain the occurrence of IBD-IBS beyond a merely random effect. Dysmotility, visceral hypersensitivity and increased mucosal permeability are the best studied ones.
https://www.ncbi.nlm.nih.gov/pmc/articles/pmc4734957/ said...
Even though quiescent IBD patients with IBS-like symptoms are not at risk of suffering direct complications of IBD such as perforations, abscesses or toxic megacolon, their symptoms can be very intense and significantly reduce their QoL, maybe as much as an actual flare does. ... all of them consistently show that IBD patients in remission who have IBS-like symptoms have a worse QoL and a greater probability of suffering from depression or anxiety than those who remain asymptomatic. ... an effort should be undertaken to recognize and treat this condition as satisfactorily as possible. Evidence on best management options of these patients is almost nonexistent. It seems reasonable to use the same drugs that have proven efficacy in IBS, such as antispasmodics and antidepressants, while we wait for future prospective trials.